These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11826785)

  • 21. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT.
    Schillaci O; Chiaravalloti A; Pierantozzi M; Di Pietro B; Koch G; Bruni C; Stanzione P; Stefani A
    Int J Mol Med; 2011 Nov; 28(5):881-6. PubMed ID: 21811760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism.
    Gaig C; Martí MJ; Tolosa E; Valldeoriola F; Paredes P; Lomeña FJ; Nakamae F
    Mov Disord; 2006 Nov; 21(11):1994-8. PubMed ID: 16941463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions.
    Sjøholm H; Sundsfjord J; Mellgren SI
    Acta Neurol Scand; 2002 Jan; 105(1):5-7. PubMed ID: 11903101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic accuracy of FP-CIT SPECT in patients with parkinsonism].
    Ortega Lozano SJ; Martínez Del Valle Torres MD; Jiménez-Hoyuela García JM; Gutiérrez Cardo AL; Campos Arillo V
    Rev Esp Med Nucl; 2007; 26(5):277-85. PubMed ID: 17910836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A differential diagnosis of Parkinsonism.
    Weiner WJ
    Rev Neurol Dis; 2005; 2(3):124-31. PubMed ID: 16400311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical parkinsonian syndromes.
    Hellwig S; Kreft A; Amtage F; Tüscher O; Winz OH; Hellwig B; Weiller C; Weber WA; Vach W; Meyer PT
    J Nucl Med; 2013 Dec; 54(12):2081-6. PubMed ID: 24115529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is functional imaging useful in the clinical evaluation of Parkinson's disease?].
    Remy P
    Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S57-61. PubMed ID: 12773889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroimaging in Parkinson's Disease: necessity or exaggeration?
    Śmiłowska K; Burzyńska-Makuch M; Brockhuis B; Piekarski R; Friedman A; Popek A; Sławek J
    Neurol Neurochir Pol; 2021; 55(6):536-548. PubMed ID: 34637136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.
    Thobois S; Prange S; Scheiber C; Broussolle E
    Parkinsonism Relat Disord; 2019 Feb; 59():93-100. PubMed ID: 30181086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-radionuclide brain SPECT for the differential diagnosis of parkinsonism.
    El Fakhri G; Ouyang J
    Methods Mol Biol; 2011; 680():237-46. PubMed ID: 21153385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes.
    Vlaar AM; de Nijs T; Kessels AG; Vreeling FW; Winogrodzka A; Mess WH; Tromp SC; van Kroonenburgh MJ; Weber WE
    Eur Neurol; 2008; 59(5):258-66. PubMed ID: 18264015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.
    Ba F; Martin WR
    Parkinsonism Relat Disord; 2015 Feb; 21(2):87-94. PubMed ID: 25487733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI Signs of Parkinson's Disease and Atypical Parkinsonism.
    Aludin S; Schmill LA
    Rofo; 2021 Dec; 193(12):1403-1410. PubMed ID: 34034347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Functional neuroimaging with SPECT in Parkinson's disease and Parkinsonisms].
    Lorenzo-Bosquet C; Hernández-Vara J; Castell-Conesa J; Miquel-Rodríguez F
    Rev Neurol; 2008 Apr 1-15; 46(7):430-5. PubMed ID: 18389463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Differential diagnosis of atypical Parkinsonian syndromes].
    Csóti I; Fornádi F
    Ideggyogy Sz; 2010 Mar; 63(3-4):77-86. PubMed ID: 20405664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease.
    Zijlmans J; Evans A; Fontes F; Katzenschlager R; Gacinovic S; Lees AJ; Costa D
    Mov Disord; 2007 Jul; 22(9):1278-85. PubMed ID: 17486613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.